Zhu D - Search Results

1

Genomic profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: a secondary analysis of the CLAP trial.

Huang X, He M, Peng H, Tong C, Liu Z, Zhang X, Shao Y, Zhu D, Zhang J, Yin JC, Yang F, Lan C. Huang X, et al. Among authors: zhu d. J Immunother Cancer. 2021 May;9(5):e002223. doi: 10.1136/jitc-2020-002223. J Immunother Cancer. 2021. PMID: 34011535 Free PMC article. Clinical Trial.

2

Clinical Application of Circulating Tumor DNA in the Genetic Analysis of Patients with Advanced GIST.

Xu H, Chen L, Shao Y, Zhu D, Zhi X, Zhang Q, Li F, Xu J, Liu X, Xu Z. Xu H, et al. Among authors: zhu d. Mol Cancer Ther. 2018 Jan;17(1):290-296. doi: 10.1158/1535-7163.MCT-17-0436. Epub 2017 Nov 13. Mol Cancer Ther. 2018. PMID: 29133619

3

SMAD4 and NF1 mutations as potential biomarkers for poor prognosis to cetuximab-based therapy in Chinese metastatic colorectal cancer patients.

Mei Z, Shao YW, Lin P, Cai X, Wang B, Ding Y, Ma X, Wu X, Xia Y, Zhu D, Shu Y, Fu Z, Gu Y. Mei Z, et al. Among authors: zhu d. BMC Cancer. 2018 Apr 27;18(1):479. doi: 10.1186/s12885-018-4298-5. BMC Cancer. 2018. PMID: 29703253 Free PMC article.

4

Next-generation sequencing reveals mutational accordance between cell-free DNA from plasma, malignant pleural effusion and ascites and directs targeted therapy in a gastric cancer patient.

Zhou S, Xu B, Qi L, Zhu D, Liu B, Wei J. Zhou S, et al. Among authors: zhu d. Cancer Biol Ther. 2019;20(1):15-20. doi: 10.1080/15384047.2018.1504720. Epub 2018 Aug 17. Cancer Biol Ther. 2019. PMID: 30118648 Free PMC article.

5

Distinct genomic traits of acral and mucosal melanomas revealed by targeted mutational profiling.

Zou Z, Ou Q, Ren Y, Lv Q, Qin L, Zhao L, Su S, Wu X, Bao H, Wang A, Zhu D, Wang X, Shao YW, Liu B. Zou Z, et al. Among authors: zhu d. Pigment Cell Melanoma Res. 2020 Jul;33(4):601-611. doi: 10.1111/pcmr.12865. Epub 2020 Jan 27. Pigment Cell Melanoma Res. 2020. PMID: 31944535

6

Genetic characterisation of sarcomatoid carcinomas reveals multiple novel actionable mutations and identifies KRAS mutation as a biomarker of poor prognosis.

Ding Y, Shao Y, Na C, Yin JC, Hua H, Tao R, Jiang Y, Hu R, He X, Miao C, Zhu D, Zhang Z. Ding Y, et al. Among authors: zhu d. J Med Genet. 2022 Jan;59(1):10-17. doi: 10.1136/jmedgenet-2020-107083. Epub 2020 Oct 28. J Med Genet. 2022. PMID: 33115932

7

The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors.

Jin Y, Chen DL, Wang F, Yang CP, Chen XX, You JQ, Huang JS, Shao Y, Zhu DQ, Ouyang YM, Luo HY, Wang ZQ, Wang FH, Li YH, Xu RH, Zhang DS. Jin Y, et al. Mol Cancer. 2020 Oct 30;19(1):154. doi: 10.1186/s12943-020-01274-7. Mol Cancer. 2020. PMID: 33126883 Free PMC article.

8

Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial.

Chen X, Wu X, Wu H, Gu Y, Shao Y, Shao Q, Zhu F, Li X, Qian X, Hu J, Zhao F, Mao W, Sun J, Wang J, Han G, Li C, Xia Y, Seesaha PK, Zhu D, Li H, Zhang J, Wang G, Wang X, Li X, Shu Y. Chen X, et al. Among authors: zhu d, zhu f. J Immunother Cancer. 2020 Nov;8(2):e001240. doi: 10.1136/jitc-2020-001240. J Immunother Cancer. 2020. PMID: 33172881 Free PMC article. Clinical Trial.

9

Identification of Novel Alectinib-Resistant ALK Mutation G1202K with Sensitization to Lorlatinib: A Case Report and in silico Structural Modelling.

Yang P, Cao R, Bao H, Wu X, Yang L, Zhu D, Zhang L, Peng L, Cai Y, Zhang W, Shao Y. Yang P, et al. Among authors: zhu d. Onco Targets Ther. 2021 Mar 25;14:2131-2138. doi: 10.2147/OTT.S293901. eCollection 2021. Onco Targets Ther. 2021. PMID: 33790576 Free PMC article.

10

Genetic Profiling of Cell-Free DNA From Pleural Effusion in Advanced Lung Cancer as a Surrogate for Tumor Tissue and Revealed Additional Clinical Actionable Targets.

Tu HY, Li YS, Bai XY, Sun YL, Zheng MY, Ke EE, Liao RQ, Jiang BY, Lin JX, Huang J, Xu BF, Yang JJ, Zhang XC, Zhou Q, Wang BC, Chen HJ, Tong X, Yu R, Wu X, Zhu D, Wu YL. Tu HY, et al. Among authors: zhu d. Clin Lung Cancer. 2022 Mar;23(2):135-142. doi: 10.1016/j.cllc.2021.09.002. Epub 2021 Sep 20. Clin Lung Cancer. 2022. PMID: 34645582

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

11,075 results

Search Page